Skip to main content
Quest PharmaTech Inc. logo

Quest PharmaTech Inc. — Investor Relations & Filings

Ticker · QPT ISIN · CA74836M1068 TSXV Manufacturing
Open in API
Filings indexed 107 across all filing types
Latest filing 2025-09-26 Management Reports
Country CA Canada
Listing TSXV QPT

About Quest PharmaTech Inc.

https://questpharmatech.com/

Quest PharmaTech Inc. is a biopharmaceutical company focused on the discovery and development of novel therapeutics. The company's pipeline targets applications in cancer treatment, dermatology, and wound healing, utilizing both proprietary technologies, such as transdermal delivery systems, and strategic investments. A core proprietary asset is the antibody Mab AR 9.6, licensed for targeted cancer therapy against truncated O-glycan on MUC16. Quest also maintains significant ownership interests in associated entities, including OncoVent, and holds convertible bond interests in OncoQuest Pharmaceuticals, Inc. (OQP). These OQP bonds are planned to be exchanged into shares of Canaria Bio, a company developing immunotherapy assets, providing Quest with an expected ownership stake of approximately 23% in Canaria Bio upon conversion.

Recent filings

Filing Released Lang Actions
Interim MD&A - English.pdf
Management Reports Classification · 92% confidence The document is titled “Management’s Discussion & Analysis For the six months ended July 31, 2025,” and contains narrative commentary, analysis of operations, liquidity, risks, and accounting policies prepared alongside unaudited condensed interim consolidated financial statements under IFRS and Canadian securities regulations. It is not merely a brief announcement but the full MD&A section for an interim period. This fits the definition of a Management Report (MDA) rather than an Annual Report, Earnings Release, or simple announcement.
2025-09-26 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 55% confidence The document is a Form 52-109FV2 “Certification of Interim Filings” by the CFO under Canadian National Instrument 52-109. It is an attestation certificate, not the interim financial report or MD&A itself, nor an announcement of a report’s publication. It does not match any specific report category (IR) or announcement (RPA) and thus falls into the general regulatory filings fallback category.
2025-09-26 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 75% confidence The document is a Form 52-109FV2 Venture Issuer Basic Certificate, a statutory certification under Canadian National Instrument 52-109 accompanying interim filings. It is not the interim report (IR) itself, nor an announcement of publication, but a required regulatory form. It does not fit any specific reporting category (e.g., 10-K, IR, ER) and serves as a compliance filing. Thus, it best fits the fallback category for miscellaneous regulatory filings: RNS.
2025-09-26 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Interim Consolidated Financial Statements' for Quest PharmaTech Inc. for the three and six months ended July 31, 2025. It contains comprehensive financial statements (Statement of Financial Position, Statement of Loss and Comprehensive Loss, Statement of Changes in Shareholders' Equity, and Statement of Cash Flows) and detailed notes to the financial statements. This fits the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2025
2025-09-26 English
Notice of meeting - English.pdf
Proxy Solicitation & Information Statement Classification · 60% confidence The document is a formal notice of the Annual General Meeting of shareholders, including meeting date, record date, agenda items, proxy voting instructions, and reference to the Management Information Circular. It is sent to shareholders to inform them of the meeting and solicit their votes via proxy. This falls under Proxy Solicitation & Information Statement materials rather than the AGM presentation, the full annual report, or a simple announcement. Therefore, it should be classified as PSI (Proxy Solicitation & Information Statement).
2025-07-29 English
Management information circular - English.pdf
Proxy Solicitation & Information Statement Classification · 96% confidence The document consists of a Notice of Annual General Meeting and a Management Information Circular (proxy solicitation materials) provided to shareholders in advance of the AGM to request votes and furnish meeting details. This aligns directly with the Proxy Solicitation & Information Statement category (Code: PSI).
2025-07-29 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.